Trending
Resveratrol sharply reduced CRP in a meta-analysis of diabetes patients — but the evidence was rated low quality
This is one of the first meta-analyses to suggest resveratrol might lower inflammation in type 2 diabetes, but the low-quality evidence means the finding is far from settled — and it may not apply to healthy people.
Resveratrol supplements significantly lowered C-reactive protein (CRP), a marker of systemic inflammation, in people with type 2 diabetes. However, the same analysis found no effect on two other inflammatory markers (IL-6 and TNF-alpha), and the overall quality of the six underlying trials was rated low to very low. The dose used wasn't specified, so it's unclear how much resveratrol might be needed to see this effect.
Where this fits in the evidence
This is among the first studies we've indexed on Resveratrol for Reduced C-Reactive Protein Levels — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 533
- 2025-01-13
- Frontiers in endocrinology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.